| 20-1572 |
Ramon D. Johnson, II v. Novartis Pharmaceuticals Corporation, et al. |
Fifth Circuit |
2021-05-13 |
Denied |
Response WaivedRelisted (2) |
brand-name-liability brand-name-manufacturer FDA-approval generic-drug generic-drug-liability label-defect leave-to-amend preemption product-liability state-law-claims texas-presumption-of-no-liability unapproved-indication |
In Pliva, Inc. v. Mensing 564 U.S. 604 (2011)
the only question before this Court was whether a
state law duty for a generic drug manufacturer to
p… |